(-0.30%) 5 020.48 points
(0.28%) 37 923 points
(-0.41%) 15 594 points
(-3.21%) $79.30
(-2.66%) $1.938
(0.69%) $2 318.70
(0.62%) $26.82
(1.58%) $963.15
(-0.08%) $0.936
(-0.16%) $11.08
(0.08%) $0.801
(-0.05%) $93.40
0.00% € 23.40
Live Chart Being Loaded With Signals
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo...
Stats | |
---|---|
Dzisiejszy wolumen | 32.00 |
Średni wolumen | 520.00 |
Kapitalizacja rynkowa | 280.57M |
EPS | €0 ( 2024-04-07 ) |
Następna data zysków | ( €0 ) 2024-05-14 |
Last Dividend | €0.490 ( 2023-06-29 ) |
Next Dividend | €0 ( N/A ) |
P/E | 18.72 |
ATR14 | €0 (0.00%) |
PharmaSGP Holding SE Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PharmaSGP Holding SE Finanse
Annual | 2022 |
Przychody: | €85.82M |
Zysk brutto: | €76.79M (89.48 %) |
EPS: | €1.000 |
FY | 2022 |
Przychody: | €85.82M |
Zysk brutto: | €76.79M (89.48 %) |
EPS: | €1.000 |
Financial Reports:
No articles found.
PharmaSGP Holding SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0.490 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.450 | 2022-06-16 |
Last Dividend | €0.490 | 2023-06-29 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | €0.940 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.99 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.90 | |
Div. Directional Score | 8.25 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SZG.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
DBK.DE | Ex Dividend Junior | 2023-05-18 | Sporadic | 0 | 0.00% | |
MBG.DE | Ex Dividend Knight | 2023-05-04 | Annually | 0 | 0.00% | |
47T.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
VOS.DE | Ex Dividend Junior | 2023-05-25 | Sporadic | 0 | 0.00% | |
EUZ.DE | Ex Dividend Knight | 2023-06-08 | Annually | 0 | 0.00% | |
OEWA.DE | Ex Dividend Knight | 2023-05-02 | Annually | 0 | 0.00% | |
ALD.DE | Ex Dividend Knight | 2023-08-10 | Quarterly | 0 | 0.00% | |
HAG.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
RHK.DE | Ex Dividend Junior | 2023-06-09 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.114 | 1.200 | 6.20 | 7.44 | [0 - 0.3] |
returnOnEquityTTM | 0.451 | 1.500 | 6.10 | 9.15 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.56 | 0.800 | 2.21 | 1.766 | [1 - 3] |
quickRatioTTM | 2.05 | 0.800 | 2.66 | 2.13 | [0.8 - 2.5] |
cashRatioTTM | 1.546 | 1.500 | 2.52 | 3.78 | [0.2 - 2] |
debtRatioTTM | 0.00766 | -1.500 | 9.87 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.89 | 1.000 | 8.93 | 8.93 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.18 | 2.00 | 9.27 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.12 | 2.00 | 8.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.906 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.246 | 1.000 | 7.08 | 7.08 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 25.94 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.742 | 0.800 | 8.39 | 6.71 | [0.5 - 2] |
Total Score | 11.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.72 | 1.000 | 8.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.451 | 2.50 | 7.49 | 9.15 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.12 | 2.00 | 9.29 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.09 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.18 | 2.00 | 9.27 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.268 | 1.000 | 5.81 | 0 | [0.1 - 0.5] |
Total Score | 4.90 |
PharmaSGP Holding SE
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej